Ovid Therapeutics Inc. Common Stock
OVIDOvid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for rare neurological disorders. Founded to address unmet medical needs, the company specializes in leveraging its expertise in neuroscience to bring innovative therapies to patients with conditions such as rare epilepsies and other central nervous system disorders.
Company News
Ovid Therapeutics announced a CEO succession plan with Meg Alexander becoming CEO on January 1, 2026, and Dr. Jeremy M. Levin transitioning to Executive Chair. The company reported positive Phase 1 results for OV329, a next-generation GABA-AT inhibitor, and continues advancing its KCC2 direct activator portfolio.
Stay up to date on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Ovid Therapeutics (NASDAQ:OVID) in the last three months. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bu...
